Pasithea Therapeutics Corp.
KTTA Nasdaq
SEC CIK 1841330
Follow Pasithea Therapeutics Corp.
Weekly email: filings, results, news
Net income
−$5.3M
−41.9% vs same quarter last year
EPS, diluted
−$0.16
+75.8% vs same quarter last year
Operating cash flow
−$4.7M
−21.7% vs same quarter last year
Operating income
−$5.7M
−49.9% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY25 | −$20.4M |
| FY24 | −$13.9M |
| FY23 | −$16M |
| FY22 | −$13.9M |
| FY21 | −$2.2M |
| FY20 | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | - |
| FY24 | - |
| FY23 | −$12.8M |
| FY22 | −$14.7M |
| FY21 | −$3.2M |
| FY20 | - |
News
No stories filed under Pasithea Therapeutics Corp. yet - coverage appears here as the news feed clusters it.